Multinational Pharmaceutical Companies Post Mixed Q311 China Results

BMI View: China is the world's most attractive emerging pharmaceutical market. The key driver of growth is the government's commitment to providing affordable universal healthcare. We highlight that while foreign investors are increasing their commitment to the country, not everyone will achieve a stellar financial performance. The lack of data on sales in China in several 'big pharma' financial reports suggests to us that they are either seeing strong growth in sales of particular drugs or general strong growth, albeit from a lower base.

To read the full article, please choose one of the following options: